Please Wait...

Bioclinica Announces Senior Leadership Change

Euan Menzies, Chairman of Board of Directors, Named Executive Chairman and Interim CEO | President and CEO David Herron to Step Down

December 20, 2019

PRINCETON, N.J., December 20, 2019 – Bioclinica, a leading provider of clinical science and
technology expertise to assist the life science industry, today announces that David Herron,
Bioclinica’s President and Chief Executive Officer, will be leaving the company to pursue other
business interests. Euan Menzies, the Chairman of Bioclinica’s Board of Directors, will assume the
role of Executive Chairman and interim Chief Executive Officer. To ensure a seamless transition of
leadership responsibilities, Mr. Herron will remain with the Company in an advisory capacity until
the end of January 2020.
“On behalf of everyone at Bioclinica, I would like to thank David for his significant contributions to
the company,” said Menzies. “During the past several years, Bioclinica has achieved numerous
milestones, including improved financial performance and the broadening of its global presence.
We have an exceptional leadership and employee team; and are now well positioned to accelerate
the pace of investment and growth as we continue to deliver meaningful value for our clients.”

Media Contact
Samantha Cranko
Bioclinica
+1-609-779-5858
samantha.cranko@bioclinica.com

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance, and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

In our latest blog post, we review the "burdens" of #CTMS implementation - and how better solutions address them.… https://t.co/vcyS2gvwpu
Bioclinica (3 days ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/01liAxqx0J
Bioclinica (4 days ago)
Rapid implementation. Increased control & efficiency. Out-of-the-box configuration. Turn-key validation. Cost savin… https://t.co/XO53jwd2DV
Bioclinica (2 weeks ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/ZtxVWMlznP
Bioclinica (2 weeks ago)
Bioclinica's #IRT uses an agile delivery methodology, which means flexible configuration and customization, and del… https://t.co/SRd2uNscWc
Bioclinica (2 weeks ago)
Presenting Bioclinica CTMS: a rapid startup #CTMS that takes 2 weeks to implement, rather than months. Bioclinica C… https://t.co/9IH38ix6nW
Bioclinica (3 weeks ago)